Indonesia

Studies/Projects
Publications

1 to 3 HP

Post Date:

2023-01-24

Countries:

Protocol Title: A Randomized Trial Comparing Treatment Completion of Daily Rifapentine & Isoniazid for One Month (1HP) to Weekly Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in HIV-negative Household Contacts of Recently Diagnosed Tuberculosis Patients, The “One...

Epidemiologic Factors Associated with TB Treatment Outcomes Across Report International Consortia

Post Date:

2021-08-12

Countries:

Rationale: RePORT International was designed to enable cross-consortium data analysis. Now that a large number of consortium sites have completed participant enrollment in Common Protocol Cohort A, we can proceed with large-scale analysis of aligned RePORT data. The current study will harmonize and...

Pediatric tuberculous meningitis: model-based approach to determining optimal doses of anti-tuberculosis drugs for children

Post Date:

2015-10-22

Countries:

Clinical Sites:

Publication:

Clinical Pharmacology and Therapeutics

Pediatric tuberculous meningitis (TBM) is a highly morbid, often fatal disease. Standard treatment includes isoniazid, rifampin, pyrazinamide, and ethambutol. Current rifampin dosing achieves low cerebrospinal fluid (CSF) concentrations, and CSF penetration of ethambutol is poor. In adult...

RePORT International: advancing tuberculosis biomarker research through global collaboration

Post Date:

2015-10-15

Countries:

Clinical Sites:

Publication:

Clinical Infectious Diseases

Progress in tuberculosis clinical research is hampered by a lack of reliable biomarkers that predict progression from latent to active tuberculosis, and subsequent cure, relapse, or failure. Regional Prospective Observational Research for Tuberculosis (RePORT) International represents a...